Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA
Glavni autori: Yazdany, Jinoos, Dudley, R. Adams, Lin, Grace A., Chen, Randi, Tseng, Chien-Wen
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Research Letter
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142992/
https://ncbi.nlm.nih.gov/pubmed/30193264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.7316
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items